LivaNova (LIVN) Gains from Investment Securities (2019 - 2026)
LivaNova (LIVN) reported Gains from Investment Securities of $10.7 million for Q1 2026, up 1055.64% on a YoY basis from $922000.0 in Q1 2025, and up 345.26% sequentially from $2.4 million in Q4 2025.
LivaNova (LIVN) Gains from Investment Securities (2019 - 2026) Analysis & Trends
LivaNova (LIVN) has 8 years of Gains from Investment Securities data on file, last reported at $10.7 million in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities rose 1055.64% year-over-year to $10.7 million; the trailing twelve-month figure through Mar 2026 stood at $17.6 million (up 302.43% YoY), and the FY2025 full-year result was $7.9 million, up 136.94% from the prior year.
- Gains from Investment Securities improved to $10.7 million in Q1 2026, from $2.4 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $10.7 million in Q1 2026 to a low of -$23.6 million in Q2 2022.
- A 5-year average of $76882.4 and a median of $1.8 million in 2025 frame the typical range for Gains from Investment Securities.
- Across the five-year window, Gains from Investment Securities plunged 932.89% in 2022 and surged 2559.09% in 2025, its largest moves.
- Tracing LIVN's Gains from Investment Securities over 5 years: stood at $3.4 million in 2022, then surged by 40.73% to $4.8 million in 2023, then sank by 38.52% to $3.0 million in 2024, then retreated by 19.64% to $2.4 million in 2025, then surged by 345.26% to $10.7 million in 2026.
- Business Quant data shows LIVN's Gains from Investment Securities at $10.7 million in Q1 2026, $2.4 million in Q4 2025, and $1.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn |
| 10 | LivaNova | 4.40 Bn | 3.86 Bn | 243.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.66 Mn |
| Mar 31, 2026 | 10.66 Mn |
| Dec 31, 2025 | 2.39 Mn |
| Dec 31, 2025 | 2.39 Mn |
| Sep 30, 2025 | 1.76 Mn |
| Sep 30, 2025 | 1.76 Mn |
| Jun 30, 2025 | 2.79 Mn |
| Jun 30, 2025 | 2.79 Mn |
| Mar 31, 2025 | 922,000.00 |
| Mar 31, 2025 | 922,000.00 |
| Dec 31, 2024 | 2.98 Mn |
| Dec 31, 2024 | 2.98 Mn |
| Sep 30, 2024 | 66,000.00 |
| Sep 30, 2024 | 66,000.00 |
| Jun 30, 2024 | 405,000.00 |
| Jun 30, 2024 | 405,000.00 |
| Mar 31, 2024 | -133,000.00 |
| Mar 31, 2024 | -133,000.00 |
| Dec 31, 2023 | 4.84 Mn |
| Dec 31, 2023 | 4.84 Mn |